BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Johnson & Johnson Stock Rises on EU Committee Backing for Muscle-Weakness Drug
Johnson & Johnson Stock Rises on EU Committee Backing for Muscle-Weakness Drug
19
1
BTCCSquare news:
Johnson & Johnson shares climbed after the European Medicines Agency's committee endorsed its Nipocalimab treatment for generalized myasthenia gravis. The therapy targets harmful antibodies in patients aged 12+ with specific gMG biomarkers.
The CHMP's positive opinion marks a regulatory milestone for the FcRn-blocking antibody. gMG patients suffer debilitating symptoms including muscle weakness, vision impairment, and respiratory distress—all addressable through this novel adjunctive therapy.
By:
